1. Home
  2. TBBK vs APLS Comparison

TBBK vs APLS Comparison

Compare TBBK & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBBK
  • APLS
  • Stock Information
  • Founded
  • TBBK 1999
  • APLS 2009
  • Country
  • TBBK United States
  • APLS United States
  • Employees
  • TBBK N/A
  • APLS N/A
  • Industry
  • TBBK Major Banks
  • APLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • TBBK Finance
  • APLS Health Care
  • Exchange
  • TBBK Nasdaq
  • APLS Nasdaq
  • Market Cap
  • TBBK 2.4B
  • APLS 2.2B
  • IPO Year
  • TBBK 2004
  • APLS 2017
  • Fundamental
  • Price
  • TBBK $51.07
  • APLS $17.69
  • Analyst Decision
  • TBBK Buy
  • APLS Buy
  • Analyst Count
  • TBBK 3
  • APLS 19
  • Target Price
  • TBBK $65.33
  • APLS $37.67
  • AVG Volume (30 Days)
  • TBBK 475.5K
  • APLS 2.1M
  • Earning Date
  • TBBK 07-24-2025
  • APLS 07-31-2025
  • Dividend Yield
  • TBBK N/A
  • APLS N/A
  • EPS Growth
  • TBBK 20.50
  • APLS N/A
  • EPS
  • TBBK 4.42
  • APLS N/A
  • Revenue
  • TBBK $502,282,000.00
  • APLS $775,839,000.00
  • Revenue This Year
  • TBBK N/A
  • APLS $1.01
  • Revenue Next Year
  • TBBK $6.71
  • APLS $22.14
  • P/E Ratio
  • TBBK $11.56
  • APLS N/A
  • Revenue Growth
  • TBBK 10.02
  • APLS 48.04
  • 52 Week Low
  • TBBK $33.77
  • APLS $16.10
  • 52 Week High
  • TBBK $65.84
  • APLS $42.47
  • Technical
  • Relative Strength Index (RSI)
  • TBBK 48.64
  • APLS 42.98
  • Support Level
  • TBBK $49.66
  • APLS $18.26
  • Resistance Level
  • TBBK $51.43
  • APLS $19.96
  • Average True Range (ATR)
  • TBBK 1.43
  • APLS 0.84
  • MACD
  • TBBK -0.21
  • APLS -0.08
  • Stochastic Oscillator
  • TBBK 36.77
  • APLS 19.22

About TBBK The Bancorp Inc

The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.

About APLS Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Share on Social Networks: